Lupin’s margin falls sharply sequentially despite 32.04% YoY revenue growth
Costs grew faster than revenue in Q1FY27, while a higher tax rate limited net-profit growth to +16.01% YoY.
Filed 06 Aug 2026, 21:53 IST · after market close · Lupin Ltd (LUPIN)
Key takeaways
- Consolidated revenue grew +32.04% YoY while expenses rose +28.32%, allowing operating margin to expand 2.05 percentage points to 29.60%.
- Sequentially, expenses grew +16.80% against revenue growth of +10.73%, cutting operating margin by 3.65 percentage points.
- Net profit increased only +16.01% YoY as the tax rate rose 16.05 percentage points to 29.76%, while other income contributed 6.46% of pre-tax profit.
Price around the results
Revenue growth remained broad-based, but sequential momentum lost operating leverage
Lupin’s consolidated revenue grew +32.04% YoY, with expenses rising more slowly at +28.32%; that spread drove a 2.05-percentage-point improvement in operating margin. Management said India’s chronic business grew 21.5% in Q1 against IPM growth of 16.8%, while India volume growth was 6.1%. Sequentially, revenue increased +10.73%, but expenses rose +16.80%, so operating profit declined -1.45% and margin narrowed 3.65 percentage points.
Higher tax and depreciation diluted the profit conversion
Net profit grew +16.01% YoY, well below the +42.52% increase in pre-tax profit, as the tax rate rose 16.05 percentage points to 29.76%. Interest expense increased +19.49% YoY and depreciation rose +51.46%, adding to the gap between operating profit and pre-tax profit. Other income was 6.46% of pre-tax profit, so it supported earnings but was not the main driver of the quarter. Sequentially, the tax rate increased 5.94 percentage points, helping push net profit down -3.52% despite pre-tax profit growth of +4.63%.
Margin stayed above the healthcare peer median but reversed its Q4 peak
Operating margin rose from 27.55% in Q1FY26 to 33.22% in Q2FY26 and then moved to 31.56%, 33.25% and 29.60% over the next three quarters; Q1FY27 therefore ended the recent uptrend rather than marking a third consecutive decline. Lupin’s margin was 7.06 percentage points above the 22.54% median for the 48 healthcare peers that had reported the same quarter. Management said Mirabegron and select products faced a mid-single-digit price decline because of additional competition.
Management outlined a wider product and channel pipeline
Management said Lupin plans to launch more than 20 products and file more than 15 ANDAs in FY27. The company also said it is expanding its diagnostics platform across India, its Extra-Urban division Uday and hospital channels, alongside a digital beyond-the-pill offering. For the longer term, management said it targets more than 100 NPLs and at least approximately 65% complex-product revenue share by FY31, and plans to launch more than five biosimilars by FY31.
No immediate market reaction; past results usually drew modest moves
The consolidated results were filed after market close, so there was no reported market reaction at the time of this note. Across the last eight results, Lupin’s stock rose after three and fell after five, with a median absolute move of 0.83%; the recent moves ranged from -3.28% to +0.83%, indicating that the usual response has been mixed and generally modest.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹8,277 cr | ₹7,475 cr | +10.73% | +32.04% |
| Other income | ₹130 cr | ₹9 cr | +1290.61% | +64.85% |
| Expenses | ₹5,827 cr | ₹4,989 cr | +16.80% | +28.32% |
| Operating profit | ₹2,450 cr | ₹2,486 cr | -1.45% | +41.82% |
| Operating margin (%) | 29.60% | 33.25% | — | — |
| Interest | ₹110 cr | ₹120 cr | -8.75% | +19.49% |
| Depreciation | ₹453 cr | ₹447 cr | +1.36% | +51.46% |
| Profit before tax | ₹2,017 cr | ₹1,928 cr | +4.63% | +42.52% |
| Tax | ₹600 cr | ₹459 cr | +30.71% | +209.35% |
| Net profit | ₹1,417 cr | ₹1,469 cr | -3.52% | +16.01% |
| EPS (₹) | ₹30.95 | ₹31.96 | -3.16% | +15.92% |
Operating margin of 29.60% compares with a Healthcare sector median of 22.54% across 48 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- India chronic business grew 21.5% in Q1, versus IPM growth of 16.8%.
- India recorded 6.1% volume growth in Q1.
Guidance & outlook
- Lupin expects IRF to outperform IPM by 1.2–1.3 times.
- Lupin plans to launch more than 20 products in FY27.
- Lupin plans to file more than 15 ANDAs in FY27.
- Lupin targets more than 100 NPLs and at least approximately 65% complex-product revenue share by FY31.
- Lupin plans to launch more than five biosimilars by FY31.
Expansion
- Lupin is expanding its diagnostics platform across India.
- Lupin plans to expand its Extra-Urban division, Uday.
- Lupin plans a strategic expansion in hospital channels.
New products
- Lupin launched Luforbec in Spain through a strategic partnership with Laboratorios ERN.
New initiatives
- Lupin is pursuing a beyond-the-pill approach with digital offerings.
- Lupin plans to transform quality into a future-ready, digitally enabled function.
Problems & risks
- Mirabegron and select products faced a mid-single-digit price decline due to additional competition.
What to watch
- Whether operating margin recovers from 29.60% after the 3.65-percentage-point sequential decline.
- Whether expenses continue to grow faster than revenue after the Q1 gap of 16.80% versus 10.73%.
- Progress against management’s stated FY27 plans to launch more than 20 products and file more than 15 ANDAs.